Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Zealand extends digital mammography:

This article was originally published in Clinica

Executive Summary

Digital mammography was praised by New Zealand's health minister Pete Hodgson at the opening of a NZ$3.8m (US$2.8m) facility in Dunedin (the second-largest city in the South Island) yesterday. It will be the country's second such facility. Benefits listed by Mr Hodgson include: shorter screening process; faster results; and electronically transferable images. Each year, New Zealand provides 150,000 free mammograms to women between the ages of 45-69 under the national programme BreastScreen Aotearoa, and the number of women getting screened is rising. Breast cancer deaths stand at around 630 annually, but Mr Hodgson said that screening reduces the chance of death for women between the ages of 45 and 69 by 20-35%. At the same launch event, a new mobile breast screening can was added to the programme's fleet of 10.

You may also be interested in...



Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel